{
    "clinical_study": {
        "@rank": "41856", 
        "arm_group": [
            {
                "arm_group_label": "The Long protocol", 
                "arm_group_type": "Experimental", 
                "description": "Patients in the group A received a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) which started on day 21 of preceding cycle at a dose of 0.1 mg/day. On the second day of menstruation HMG was started and this was associated with reduction of triptorelin to 0.05 mg/day. This reduced daily dose was administered until the day hCG was given. Growth hormone co-treatment was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration."
            }, 
            {
                "arm_group_label": "The Short protocol", 
                "arm_group_type": "Experimental", 
                "description": "The short agonist protocol was started on cycle day 1 with triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. Human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) were also administered starting from days 2 to 3 of cycle. The dose was adjusted for each patient according to the diameter of the follicles detected in their follow up ultrasound. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration."
            }, 
            {
                "arm_group_label": "The Antagonist protocol", 
                "arm_group_type": "Experimental", 
                "description": "Gonadotrophins IM daily (HMG 75 IU, Merional, IBSA)was administrated from day 2 of the cycle. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration. The GnRH antagonist (Cetrotide) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC."
            }, 
            {
                "arm_group_label": "The Microflare protocol", 
                "arm_group_type": "Experimental", 
                "description": "the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration."
            }
        ], 
        "brief_summary": {
            "textblock": "in this study, we are trying to monitor the effect of the addition of growth hormone on the\n      different down regulation protocols ( long, short, antagonist and microflare). The outcome\n      will be primarily assessed by the clinical pregnancy rates."
        }, 
        "brief_title": "IVF/ICSI Protocols in Poor Responders With Growth Hormone", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Female Infertility Due to Diminished Ovarian Reserve", 
        "condition_browse": {
            "mesh_term": [
                "Infertility", 
                "Infertility, Female"
            ]
        }, 
        "detailed_description": {
            "textblock": "Poor responders undergoing IVF/ICSI cycles have emerged as a major problem. the need to find\n      a proper stimulation protocol is a must. in this study we are trying to detect the best\n      stimulation protocol ,in addition to growth hormone ,that can give the highest pregnancy\n      rates in these patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        ESHRE consensus 2011,At least two of the following three features must be present:\n\n          -  Advanced maternal age (\u226540 years) or any other risk factor for POR;\n\n          -  A previous POR (\u22643 oocytes with a conventional stimulation protocol);\n\n          -  An abnormal ovarian reserve test (i.e. AFC < 5-7 follicles or AMH < 0.5 -1.1 ng/ml).\n\n        Exclusion Criteria:\n\n          -  female patients with causes of infertility other than poor ovarian reserve\n\n          -  females suffering from congenital or acquired uterine anomalies\n\n          -  females with focal uterine lesions\n\n          -  females who had previous ovarian surgeries\n\n          -  females with history of previous exposure to radiotherapy , or chemotherapy\n\n          -  females refusing to get enrolled in the study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "287", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01897324", 
            "org_study_id": "WHC2013"
        }, 
        "intervention": {
            "arm_group_label": [
                "The Long protocol", 
                "The Short protocol", 
                "The Antagonist protocol", 
                "The Microflare protocol"
            ], 
            "intervention_name": "Growth hormone (Norditropin, Novo nordisk)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Hormones", 
                "Menotropins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Poor Ovarian Response", 
            "Poor Responders", 
            "IVF/ICSI", 
            "Growth Hormone"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "dinadakhly@gmail.com", 
                "last_name": "Dina M Dakhly, MD", 
                "phone": "01003498919", 
                "phone_ext": "002"
            }, 
            "facility": {
                "address": {
                    "city": "Giza", 
                    "country": "Egypt", 
                    "state": "Cairo", 
                    "zip": "12311"
                }, 
                "name": "private IVF medical center"
            }, 
            "investigator": {
                "last_name": "Dina M Dakhly, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "4", 
        "official_title": "Which is the Best IVF/ICSI Protocol to be Used in Poor Responders Receiving Growth Hormone as an Adjuvant Treatment ? A Prospective Randomized Study", 
        "overall_contact": {
            "email": "dinadakhly@gmail.com", 
            "last_name": "Dina M Dakhly, MD", 
            "phone": "01003498919", 
            "phone_ext": "002"
        }, 
        "overall_official": {
            "affiliation": "Cairo University", 
            "last_name": "Dina M Dakhly, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of oocytes retrieved on the day of vaginal egg collection guided by trans vaginal ultrasound scan , 35 hours after hCG administration.", 
            "measure": "Numbers of oocytes retrieved and number of fertilized oocytes", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01897324"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Woman's Health University Hospital, Egypt", 
            "investigator_full_name": "Dina Mohamed Refaat Dakhly", 
            "investigator_title": "lecturer of obstetrics and gynecology, cairo university", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Woman's Health University Hospital, Egypt", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Woman's Health University Hospital, Egypt", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}